Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors
Ver/Abrir
Use este enlace para citar
http://hdl.handle.net/2183/21522
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España
Colecciones
- GI-FENM - Artigos [109]
Metadatos
Mostrar el registro completo del ítemTítulo
Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donorsFecha
2015-09-10Cita bibliográfica
León-Mateos L, Mosquera J, Antón Aparicio L. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biol. 2015; 6:421-425
Resumen
[Abstract] Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are overexpressed in the majority of renal cell carcinomas. This characteristic has supported the rationale of targeting VEGF-driven tumour vascularization, especially in clear cell RCC. VEGF-inhibiting strategies include the use of tyrosine kinase inhibitors (sunitinib, axitinib, pazopanib, and sorafenib) and neutralizing antibodies such as bevacizumab.
Hypertension (HTN) is one of the most common adverse effects of angiogenesis inhibitors. HTN observed in clinical trials appears to correlate with the potency of VEGF kinase inhibitor against VEGFR-2: agents with higher potency are associated with a higher incidence of HTN. Although the exact mechanism by tyrosine kinase inhibitors induce HTN has not yet been completely clarified, two key hypotheses have been postulated. First, some studies have pointed to a VEGF inhibitors-induced decrease in nitric oxide synthase (NOS) and nitric oxide (NO) production, that can result in vasoconstriction and increased blood pressure. VEGF, mediated by PI3K/Akt and MAPK pathway, upregulates the endothelial nitric oxide synthase enzyme leading to up-regulation of NO production. So inhibition of signaling through the VEGF pathway would lead to a decrease in NO production, resulting in an increase in vascular resistance and blood pressure. Secondly a decrease in the number of microvascular endothelial cells and subsequent depletion of normal microvessel density (rarefaction) occurs upon VEGF signaling inhibition.
NO donors could be successfully used not only for the treatment of developed angiogenesis-inhibitor-induced hypertension but also for preventive effects.
Palabras clave
Tyrosine kinase inhibitors
Hypertension
Vascular endothelial growth factor
Nitric oxide
Renal cell carcinoma
Sunitinib
Hypertension
Vascular endothelial growth factor
Nitric oxide
Renal cell carcinoma
Sunitinib
Versión del editor
Derechos
Atribución-NoComercial-SinDerivadas 3.0 España
ISSN
2213-2317